SCHEMBL10171243

SCHEMBL10171243

NC(=O)C1C2C=CC(C2)C1Nc1nc(Nc2ccc(N3CCOCC3)cc2)nc2[nH]ccc12

nearest known ligand 0.63

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 15/20 0.63
JAK3 P52333 3/20 0.57
BTK Q06187 3/20 0.57
MAP3K7 O43318 3/20 0.52
KDR P35968 1/20 0.49
AURKB Q96GD4 1/20 0.49
TTK P33981 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10171186 0.92 IRAK4 (0.69) IRAK4JAK3BTKMAP3K7
SCHEMBL10171163 0.87 JAK3 (0.60) IRAK4JAK3BTKTTK
SCHEMBL10171218 0.86 IRAK4 (0.56) IRAK4MAP3K7KDRAURKB
SCHEMBL14484004 0.83 IRAK4 (0.67) IRAK4MAP3K7KDRAURKB
SCHEMBL10171979 0.83 IRAK4 (0.67) IRAK4MAP3K7KDRAURKB
SCHEMBL10171223 0.83 IRAK4 (0.62) IRAK4KDRAURKB
SCHEMBL12113703 0.83 IRAK4 (0.56) IRAK4MAP3K7KDRAURKB
SCHEMBL10172038 0.81 IRAK4 (0.63) IRAK4MAP3K7KDRAURKB
SCHEMBL10172040 0.81 IRAK4 (0.67) IRAK4JAK3BTKKDRAURKB
SCHEMBL10171531 0.81 IRAK4 (0.60) IRAK4MAP3K7KDRAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9834568-B2 Kinase inhibitors and their uses RIGEL PHARMACEUTICALS, INC. (US) 2017-12-05 US disclosed
US-20160024116-A1 Kinase Inhibitors And Their Uses MIDCAP FINANCIAL TRUST 2016-01-28 US disclosed
US-9096542-B2 Kinase inhibitors and their uses RIGEL PHARMACEUTICALS, INC. (US) 2015-08-04 US disclosed
US-20120015937-A1 Kinase Inhibitors And Their Uses RIGEL PHARMACEUTICALS, INC. (US) 2012-01-19 US disclosed
US-8053434-B2 Kinase inhibitors and their uses RIGEL PHARMACEUTICALS, INC. (US) 2011-11-08 US disclosed
US-20100069369-A1 Kinase Inhibitors And Their Uses RIGEL PHARMACEUTICALS, INC. (US) 2010-03-18 US disclosed
US-7601713-B2 Kinase inhibitors and their uses RIGEL PHARMACEUTICALS, INC. (US) 2009-10-13 US disclosed
US-7601713-B2 Kinase inhibitors and their uses RIGEL PHARMACEUTICALS, INC. (US) 2009-10-13 US disclosed
WO-2007070872-A1 KINASE INHIBITORS AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2007-06-21 WO disclosed
US-20070142402-A1 Kinase Inhibitors And Their Uses RIGEL PHARMACEUTICALS, INC. (US) 2007-06-21 US disclosed
US-20070142402-A1 Kinase Inhibitors And Their Uses RIGEL PHARMACEUTICALS, INC. (US) 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015937-A1 Kinase Inhibitors And Their Uses BTK, SYK, LYN IRAK4 239/4885JAK3 12/4885BTK 1/4885
US-20160024116-A1 Kinase Inhibitors And Their Uses BTK, SYK, LYN IRAK4 239/4885JAK3 12/4885BTK 1/4885
US-20100069369-A1 Kinase Inhibitors And Their Uses BTK, SYK, JAK2 IRAK4 293/4885JAK3 12/4885BTK 1/4885
US-20070142402-A1 Kinase Inhibitors And Their Uses BTK, SYK, LYN IRAK4 239/4885JAK3 12/4885BTK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.